Melanoma

  • Tumor of melanocytes - Melanin์„ ๋งŒ๋“œ๋Š” ์„ธํฌ(melanocytes)์—์„œ ์ƒ๊ธด ์ข…์–‘
  • ์–‘์„ฑ&์•…์„ฑ ๋‘˜ ๋‹ค ๊ฐ€๋Šฅ, ์กฐ์ง ๊ฒ€์‚ฌ๋กœ ์ง„๋‹จ.
    • Melanoticํ•œ ๊ฒฝ์šฐ cytology์—์„œ ํŠน์ด์ ์œผ๋กœ ๋ณด์ด์ง€๋งŒ (melanocyte ์˜†์— ๊นŒ๋งŒ pigmentation)
    • ๊ฒ€๊ฒŒ ์นจ์ฐฉํ•˜์ง€ ์•Š๋Š” ๊ฒฝ์šฐ๋„ ์žˆ์œผ๋ฏ€๋กœ(amelanotic) ๋ฐ˜๋“œ์‹œ ์กฐ์ง ๊ฒ€์‚ฌ!

Behavior with Locations

  • Benign : ํ”ผ๋ถ€์— ์ƒ๊น€, ์–‘์„ฑ.
  • Malignant : ๋นจ๋ฆฌ ์ž๋ผ๋Š” ํ”ผ๋ถ€์— ์ƒ๊น€, ์•…์„ฑ, ์˜ˆํ›„๊ฐ€ ์•ˆ ์ข‹์Œ.
    • ๋นจ๋ฆฌ ์ž๋ผ๋Š” ์„ธํฌ : oral cavity, mucocutaneous ๊ฒฝ๊ณ„๋ถ€, nailbed(์†ํ†ฑ์ด ์ž๋ผ๋Š” ๋ฟŒ๋ฆฌ ๋ถ€๋ถ„).
    • Malignant melanoma๋ผ๊ณ  ํ•˜๋ฉด ๋ฌด์กฐ๊ฑด ์ด ์…‹ ์ค‘ ํ•˜๋‚˜์— ์ƒ๊ธด ๊ฒƒ.

Canine malignant ORAL melanoma

Melanoma์˜ ๋ณ‘๊ธฐ

  • 1๊ธฐ : 2cm ๋ฏธ๋งŒ์ด๊ณ  ๋ฆผํ”„์ ˆ(LN) ์ „์ด, ์›๊ฒฉ ์ „์ด(metastasis)๊ฐ€ ์—†์Œ.
  • 2๊ธฐ : 2-4cm, LN ์ „์ด์™€ ์›๊ฒฉ ์ „์ด๊ฐ€ ์—†์Œ.
  • 3๊ธฐ : 4cm ์ด์ƒ, LN ์ „์ด ์žˆ์Œ, ์›๊ฒฉ ์ „์ด ์—†์Œ.
  • 4๊ธฐ : LN ์ „์ด์™€ ์ƒ๊ด€์—†์ด ์›๊ฒฉ ์ „์ด๊ฐ€ ์žˆ์Œ. (ex-ํ์—์„œ ์ „์ด ๋ฐœ๊ฒฌ)
  • Grow rapidly (> 2cm) : ๋งค์šฐ ๋นจ๋ฆฌ ์ž๋ผ๋ฏ€๋กœ ๋ณดํ†ต 2๊ธฐ(2cm ์ด์ƒ)์ผ ๋•Œ ๋‚ด์›
  • ๋นจ๋ฆฌ ์ž๋ผ๋ฉด์„œ ๊ถค์–‘์ด ์ƒ๊น€(ulcerated)
  • Amelanoticํ•œ ๊ฒฝ์šฐ์ฒ˜๋Ÿผ, ํ•ญ์ƒ ํ‘์ƒ‰์ธ ๊ฒƒ์€ ์•„๋‹˜ (variable pigmentation)

Canine MALIGNANT melanoma (oral ํฌํ•จํ•œ ์ „์ฒด)

  • Very aggressive
    • ์ „์ด์œจ 30-75% (oral 80-90%)
    • ๊ตญ์†Œ ์žฌ๋ฐœ๋ณด๋‹ค๋Š” ๋ฆผํ”„์ ˆ์ด๋‚˜ ํ๋กœ์˜ ์ „์ด๊ฐ€ ๋งŽ์Œ (Lungs or local lymph nodes > local recurrence)
      • ๋ณดํ˜ธ์ž๋Š” ๊ตฌ๊ฐ• ์žฌ๋ฐœ๋งŒ ์‹ ๊ฒฝ์“ฐ๋ฏ€๋กœ, ํ ์ดฌ์˜์ด ์ฃผ๊ธฐ์ ์œผ๋กœ ํ•„์š”ํ•˜๋‹ค๋Š” ๊ฑธ ๊ฐ•์กฐํ•ด์•ผ ํ•จ.
  • Guarded prognosis : ์˜ˆํ›„ ๋งค์šฐ ์•ˆ ์ข‹์Œ.
    • ์ „์ด๊ฐ€ ๋„ˆ๋ฌด ๋นจ๋ผ์„œ ๋ณดํ†ต ์ˆ˜ ๊ฐœ์›”๋ฐ–์— ์ƒ์กดํ•˜์ง€ ๋ชปํ•จ.

Treatment options

  • Surgery or radiation : ์ˆ˜์ˆ ์€ ๊ตญ์†Œ์  ์ ‘๊ทผ์ด๋‹ˆ, ํ๋กœ์˜ ์ „์ด๋Š” ๋ง‰์„ ์ˆ˜ ์—†์Œ.
  • Chemotherapy : Carboplatin (๋ฐ˜์‘ < 30%)
    • ๋…์„ฑ์€ ๋†’์œผ๋‚˜ ์น˜๋ฃŒ ํšจ๊ณผ๋Š” ๋ณ„๋กœ ์—†์Œ. ์น˜๋ฃŒ๋ฅผ ๊ถŒํ•˜์ง€ ์•Š๋Š” ์ข…์–‘ ์ค‘ ํ•˜๋‚˜.
  • ์ „์‹  ์น˜๋ฃŒ๋ฅผ ํ•˜๋ฉด์„œ๋„ ๋ถ€์ž‘์šฉ์ด ๊ฑฐ์˜ ์—†๋Š” ๋ฐฑ์‹ ์ด ์ตœ๊ทผ ๊ฐœ๋ฐœ๋จ โ—

๋ฐฑ์‹  - Immunization with Xenogeneic Human DNA (์ด์ข… Human DNA ์ด์šฉ)

  • Gene for human TYROSINASE inserted into DNA plasmid
  • ์ด๋ฆ„์€ ๋ฐฑ์‹ ์ด์ง€๋งŒ ์˜ˆ๋ฐฉ์ด ์•„๋‹ˆ๋ผ ์น˜๋ฃŒํ•˜๋Š” ๋ฐฑ์‹  (=๋ฉด์—ญ ์œ ๋ฐœ)
  • Encoding tyrosinase family proteins
    • Melanin์„ ๋งŽ์ด ๋ถ„๋น„ํ•˜๋Š” ์ฃผ๋ฒ”์ธ, melanoma ์„ธํฌ ํ‘œ๋ฉด์˜ ๋‹น๋‹จ๋ฐฑ์งˆ(tyrosinase)์„ ๊ณต๊ฒฉํ•˜๋„๋ก ์œ ๋„ํ•˜๊ธฐ ์œ„ํ•ด genogenic(์ด์ข…)์˜ human DNA๋ฅผ ๊ฐœ์—๊ฒŒ ์ ‘์ข…ํ•จ.
    • ์‚ฌ๋žŒ๊ณผ ๊ฐœ์˜ tyrosinase๋Š” ๋งค์šฐ ๋น„์Šทํ•จ. ๊ฐœ์˜ DNA๋ฅผ ๋„ฃ์œผ๋ฉด ๋™์ข…์ด์–ด์„œ ๋ฉด์—ญ ํ˜•์„ฑ์ด ์•ˆ ๋˜์ง€๋งŒ, ์‚ฌ๋žŒ์˜ tyrosinase๋ฅผ vector์— ๋ผ์›Œ์„œ ์ฃผ์‚ฌํ•˜๋ฉด ์ด์— ๋Œ€ํ•œ ํ•ญ์ฒด๋ฅผ ๋งŒ๋“ค์–ด๋‚ด๋Š”๋ฐ, ๋งค์šฐ ๋น„์Šทํ•ด์„œ ๊ฐœ์˜ tyrosinase๋„ ๊ฐ™์ด ๊ณต๊ฒฉ๋จ.
  • ๋†’์€ ์ˆ˜์ค€์œผ๋กœ ๊ณผ๋ฐœํ˜„๋œ tyrosinase๋งŒ ๊ณต๊ฒฉํ•˜์ง€๋งŒ, ๋‚ฎ์€ ํ™•๋ฅ ๋กœ ๋ฐฑ๋ฐ˜์ฆ ์ƒ๊น€.

ํ•ญ์•”์ œ์˜ ๊ตฌ๋ถ„

  • 1์„ธ๋Œ€ - ์ผ๋ฐ˜ ํ•ญ์•”์ œ. ๋นจ๋ฆฌ ์ž๋ผ๋Š” ์„ธํฌ๋ฅผ ๊ณต๊ฒฉ. ๋จธ๋ฆฌ์นด๋ฝ๋„ ๊ณต๊ฒฉํ•ด์„œ ๋จธ๋ฆฌ๊ฐ€ ๋น ์ง€๊ณ , GI ์ชฝ ์„ธํฌ๋“ค๋„ ๊ณต๊ฒฉํ•ด์„œ ์œ„์—ผ๊ณผ ์žฅ์—ผ. ๊ณจ์ˆ˜๋„ ๊ณต๊ฒฉํ•ด์„œ ๋ฉด์—ญ ์ €ํ•˜, ๋นˆํ˜ˆ.
  • 2์„ธ๋Œ€ - ํ‘œ์  ํ•ญ์•” ์น˜๋ฃŒ์ œ. tyrosine-kinase inhibitor์ด๋ผ๋Š” signal์„ ํƒ€๊ฒŸ์œผ๋กœ ํ•จ. ์ •์ƒ์„ธํฌ์— ์˜ํ–ฅ ๊ฑฐ์˜ ์—†์Œ.
  • 3์„ธ๋Œ€ - ๋ฉด์—ญ ํ•ญ์•” ์น˜๋ฃŒ. ๋‚˜์ด๊ฐ€ ๋“ค๋ฉด์„œ ์•”์„ธํฌ๋ฅผ ์—†์•จ ๋งŒํผ ๋ฉด์—ญ์ด ์ผํ•˜์ง€ ๋ชปํ•จ. ์ข…์–‘์„ ์ธ์ง€ํ•˜์ง€ ๋ชปํ•˜๊ฒŒ ํ•˜๋Š” signal์„ ์—†์• ์ฃผ๋ฉด, ๋‹ค์‹œ ์ž๊ธฐ ๋ฉด์—ญ๋ ฅ์œผ๋กœ ์•”์„ธํฌ๋ฅผ ์น˜๋ฃŒํ•  ์ˆ˜ ์žˆ์Œ.

์ง€๊ธˆ ๋ฐฐ์šด ๋ฐฑ์‹ ์ด ๊ฐœ์—์„œ ์œ ์ผํ•˜๊ฒŒ ์Šน์ธ๋œ ๋ฉด์—ญ ํ•ญ์•” ์น˜๋ฃŒ์ œ.


Melanoma vaccine in dogs

  • Onceptยฎ (MERIAL ํšŒ์‚ฌ)

  • Immunotherapy (๋ฉด์—ญ์น˜๋ฃŒ) : ์˜ˆ๋ฐฉ์ด ์•„๋‹ˆ๋ผ ์น˜๋ฃŒ ๋ชฉ์  (treat, not prevent)

  • ๊ตฌ๊ฐ•ํ‘์ƒ‰์ข… ์ค‘ stage โ…ก ๋˜๋Š” โ…ข ์— ์ ์šฉ

  • ๋ถ€์ž‘์šฉ์ด ๊ฑฐ์˜ ์—†์œผ๋ฏ€๋กœ ์›ํ•œ๋‹ค๋ฉด ์จ๋„ ๋ฌด๋ฆฌ ์—†์Œ..

  • Indications (*No contraindications)

    • ์ˆ˜์ˆ ์  ์ ˆ์ œ, ๋ฐฉ์‚ฌ์„  ์น˜๋ฃŒ ์ดํ›„
    • ์ „์ด๊ฐ€ ์—†๊ณ , ๋ˆˆ์— ๋ณด์ด๋Š” ๊ตญ์†Œ ๋ณ‘๋ณ€์ด ์—†๋Š” ์ƒํƒœ์—์„œ ํšจ๊ณผ๊ฐ€ ์ข‹์Œ
  • Side effects : ๊ฑฐ์˜ ์—†์Œ (๋“œ๋ฌผ๊ฒŒ ์•ฝํ•œ ๋ถ€์ž‘์šฉ - redness, swelling, mild pain)


  • Dosing : 2์ฃผ ๋‹จ์œ„๋กœ 4๋ฒˆ Induction โ†’ 6๊ฐœ์›”์— 1๋ฒˆ Boosting


๋น„์šฉ : Induction์€ 300๋งŒ์› ์ •๋„ (+ boosting : ํšŒ๋‹น 70)

  • ์น˜๋ฃŒ ํšจ๊ณผ : ์ƒ์กด๋ฅ ์ด ์œ ์˜๋ฏธํ•˜๊ฒŒ ์ฆ๊ฐ€ (์น˜๋ฃŒํ•œ ๊ฐœ์˜ 75%์—์„œ 15๊ฐœ์›” ์ด์ƒ ์ƒ์กด)
    • ๋ฐฑ์‹ ์„ ๋งž์ง€ ์•Š์€ ์ƒํƒœ์—์„œ๋Š” maximum 3-6๊ฐœ์›”
  • ๊ตฌ๊ฐ•์ด ์•„๋‹Œ ๋‹ค๋ฅธ ์•…์„ฑ ์ข…์–‘์—์„œ๋„ ํšจ๊ณผ๊ฐ€ ์žˆ์Œ.
    • ํŠนํžˆ Nail bed, skin์—์„œ ๋ฐœ์ƒํ•œ ์ข…์–‘
    • ์ˆ˜์ˆ  โ‡’ 1๋…„ ์ƒ์กด, 2๋…„ ์ด์ƒ ์ƒ์กด๋ฅ  10%
    • ์ˆ˜์ˆ +๋ฐฑ์‹  โ‡’ 500์ผ ์ƒ์กด, 50% 2๋…„ ์ด์ƒ ์ƒ์กด๋ฅ  50%.